PMID- 24672097
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140327
LR  - 20220330
IS  - 0011-393X (Print)
IS  - 0011-393X (Linking)
VI  - 65
IP  - 6
DP  - 2004 Nov
TI  - Comparison of the effects of bimatoprost and timolol on intraocular pressure and 
      pulsatile ocular blood flow in patients with primary open-angle glaucoma: A 
      prospective, open-label, randomized, two-arm, parallel-group study.
PG  - 444-54
LID - 10.1016/j.curtheres.2005.01.004 [doi]
AB  - Abstract. BACKGROUND: The current objective of antiglaucomatous therapy is to 
      reduce intraocular pressure (IOP), and thus to preserve visual function. Many 
      ophthalmologists believe this objective is best achieved by methods that improve 
      ocular blood flow to the optic nerve head. Beta-blockers are effective ocular 
      hypotensive agents, but they can reduce choroidal blood flow. Bimatoprost, a new 
      prostamide analogue, has been shown to have a better IOP-lowering effect compared 
      with the nonselective beta-adrenergic receptor blocker timolol maleate, but 
      little is known about its effects on the vascular bed of the eye. OBJECTIVE: The 
      aim of this study was to compare the effects of bimatoprost and timolol on IOP 
      and choroidal blood flow (as measured using pulsatile ocular blood flow [pOBF]) 
      in patients with primary open-angle glaucoma (POAG). METHODS: This prospective, 
      open-label, randomized, 2-arm, parallel-group study was conducted at the Glaucoma 
      Research Centre, Department of Ophthalmology, University Hospital of Bari, Bari, 
      Italy. Patients with POAG having well-controlled IOP (<16 mm Hg) on monotherapy 
      with timolol 0.5% ophthalmic solution (2 drops per affected eye BID) for >/=12 
      months but with a progressive decrease in pOBF during the same time period were 
      randomly allocated to 1 of 2 treatment groups. One group continued monotherapy 
      with timolol, 2 drops per affected eye BID. The other group was switched (without 
      washout) to bimatoprost 0.3% ophthalmic solution (2 drops per affected eye QD [9 
      pm]). Treatment was given for 180 days. IOP and pOBF were assessed at the 
      diagnostic visit (pre-timolol), baseline (day 0), and treatment days 15, 30, 60, 
      90, and 180. Primary adverse effects (AEs) (ie, conjunctival hyperemia, 
      conjunctival papillae, stinging, burning, foreign body sensation, and 
      pigmentation of periorbital skin) were monitored throughout the study. RESULTS: 
      Thirty-eight patients were enrolled (22 men, 16 women; mean [SD] age, 51.7 [4.8] 
      years; 19 patients per treatment group; 38 eligible eyes). At 180-day follow-up 
      in the timolol group, the IOP and the pOBF remained unchanged compared with 
      baseline. In the bimatoprost group the IOP remained unchanged and the pOBF was 
      decreased by 38.9% compared with baseline (P < 0.01). All AEs were mild to 
      moderate and included conjunctival hyperemia and ocular itching (5 patients 
      [26.3%] in the bimatoprost group) and pigmentation of periorbital skin (2 
      patients [40.0%] in the bimatoprost group). The incidence of each AE was higher 
      in the bimatoprost group than in the timolol group (P = 0.008). CONCLUSIONS: In 
      this population of patients with POAG, bimatoprost was associated with increased 
      pOBF, and the reduction in pOBF associated with timolol was corrected after 
      patients were switched to bimatoprost. Bimatoprost was associated with increased 
      choroidal blood flow, beyond the levels recorded before timolol treatment. The 
      decreased IOP level achieved in the timolol group seemed to be improved further 
      by bimatoprost. Considering the potential efficacy of bimatoprost on IOP and 
      pOBF, we suggest that this new drug may represent a clinical advance in the 
      medical treatment of POAG.
FAU - Vetrugno, Michele
AU  - Vetrugno M
AD  - Departments of Ophthalmology and Otorhinolaryngology, University of Bari, Bari, 
      Italy ; Glaucoma Research Centre, Department of Ophthalmology, University 
      Hospital of Bari, Bari, Italy.
FAU - Cardascia, Nicola
AU  - Cardascia N
AD  - Departments of Ophthalmology and Otorhinolaryngology, University of Bari, Bari, 
      Italy ; Glaucoma Research Centre, Department of Ophthalmology, University 
      Hospital of Bari, Bari, Italy.
FAU - Cantatore, Francesco
AU  - Cantatore F
AD  - Departments of Ophthalmology and Otorhinolaryngology, University of Bari, Bari, 
      Italy ; Glaucoma Research Centre, Department of Ophthalmology, University 
      Hospital of Bari, Bari, Italy.
FAU - Sborgia, Carlo
AU  - Sborgia C
AD  - Departments of Ophthalmology and Otorhinolaryngology, University of Bari, Bari, 
      Italy ; Glaucoma Research Centre, Department of Ophthalmology, University 
      Hospital of Bari, Bari, Italy.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Ther Res Clin Exp
JT  - Current therapeutic research, clinical and experimental
JID - 0372621
PMC - PMC3964529
OTO - NOTNLM
OT  - bimatoprost
OT  - intraocular pressure
OT  - primary open-angle glaucoma
OT  - pulsatile ocular blood flow
OT  - timolol
EDAT- 2004/11/01 00:00
MHDA- 2004/11/01 00:01
PMCR- 2004/11/01
CRDT- 2014/03/28 06:00
PHST- 2004/10/13 00:00 [accepted]
PHST- 2014/03/28 06:00 [entrez]
PHST- 2004/11/01 00:00 [pubmed]
PHST- 2004/11/01 00:01 [medline]
PHST- 2004/11/01 00:00 [pmc-release]
AID - S0011-393X(05)00005-6 [pii]
AID - 10.1016/j.curtheres.2005.01.004 [doi]
PST - ppublish
SO  - Curr Ther Res Clin Exp. 2004 Nov;65(6):444-54. doi: 
      10.1016/j.curtheres.2005.01.004.